Calidi Biotherapeutics, Inc. Announces Pricing of $6.1 Million Public Offering
The common warrants will have an exercise price of $0.60 per share, and the Series A Common Warrants, Series B Unit Warrant and Series C Unit Warrant will be exercisable immediately.
- The common warrants will have an exercise price of $0.60 per share, and the Series A Common Warrants, Series B Unit Warrant and Series C Unit Warrant will be exercisable immediately.
- The closing of the offering is expected to occur on or about April 18, 2024, subject to the satisfaction of customary closing conditions.
- Ladenburg Thalmann & Co. Inc. is acting as sole placement agent in connection with the offering.
- The offering is being made only by means of a prospectus forming part of the effective registration statement.